MSP Uruguay adds 12 high-cost drugs at 300-peso acquisition price

Media partner

POLICY & MARKETS · SEPTEMBER 12, 2026 · LATIN AMERICA

Twelve medicines that previously cost Uruguay’s health system up to 100,000 pesos per unit will now be acquired for approximately 300 pesos, after the Ministerio de Salud Pública (MSP), Uruguay’s public health ministry, reached an agreement with the Administración de los Servicios de Salud del Estado (ASSE), the state health services body, and the country’s mutual health insurers to incorporate the drugs into the Sistema Nacional Integrado de Salud (SNIS), according to El País. The agreement was announced on 31 August 2026 and attributed to negotiations led by Health Minister Cristina Lustemberg.

The price compression implied by the agreement is striking on its face. El País reported the per-unit acquisition cost falling from as much as 100,000 pesos to around 300 pesos — a reduction that, if confirmed at scale, would represent a fundamental repricing of the affected molecules within the public and mutual system. The announcement does not specify the names of the 12 medicines, the therapeutic areas they cover, or the negotiation mechanism that produced the price reduction, leaving the durability and replicability of the arrangement difficult to assess from public information alone.

Pressure on providers, not the public purse

The structural detail most consequential for payers and industry is the reported absence of any capitation increase for providers absorbing the new coverage obligation. Mutual insurers — the private, non-profit entities that deliver care to the majority of SNIS enrollees — will be required to cover the 12 medicines without additional per-member funding, according to El País. That framing positions the agreement as a cost-transfer mechanism rather than a new public expenditure: the state extracts a pricing concession from suppliers and passes the coverage obligation to providers at the compressed price, without compensating them for the incremental actuarial load.

The Fondo Nacional de Recursos (FNR), Uruguay’s specialised high-cost drug fund, already operates at an annual budget of approximately USD 460 million, financing 87 medicines — including 26 biologics and two advanced therapies — across 45 covered pathologies, and funded 14,474 treatments during 2025, according to the Pan American Health Organization (PAHO). The 12 newly incorporated medicines appear to sit outside the FNR envelope, handled instead through the SNIS provider agreement. Whether they will eventually migrate into the FNR framework, or remain a provider-borne obligation, has not been publicly disclosed.

Alfredo Torres, the former president of the Comisión Nacional Honoraria de Altas Prestaciones y Medicamentos de Alto Costo (CONAIAMC), Uruguay’s honorary commission for high-cost treatments and medicines, was named in El País coverage of the agreement, though the article does not detail his current role in the negotiation. Undersecretary of Public Health Leonel Briozzo has been cited in related coverage by En Perspectiva in the context of the MSP’s broader access agenda, though no direct statement from him on this specific agreement has been published in the available record.

A roadmap already in motion

The agreement does not emerge in isolation. In July 2026, the MSP convened a multi-stakeholder session — drawing representatives from the Suprema Corte de Justicia, legislative health commissions, the national human rights institution, scientific societies, patient organisations, and academic faculties — to begin constructing a formal roadmap for improving access to high-cost medicines and procedures, with PAHO support, according to PAHO’s announcement of the event. That session explicitly addressed health technology assessment, price negotiation strategies, and the role of judicial amparo proceedings — constitutional injunctions — as a de facto access pathway for medicines not covered by the FNR.

The judicialisation dimension is not incidental. A 2019 PAHO inter-institutional report on high-price medicine judicialisation in Uruguay documented an 800% increase in FNR spending between 2004 and 2017, attributing part of that growth to court-ordered coverage of medicines outside the standard benefit package. Courts, per that report, frequently ruled in favour of the option that appeared to best protect the right to health, irrespective of cost-effectiveness evidence. The MSP’s current formulary expansion — negotiated rather than litigated — may be read as an attempt to pre-empt judicial pressure by bringing contested medicines into the covered benefit at a price the system can sustain.

The principal friction in that reading is implementation. A negotiated price of 300 pesos per unit is only operationally meaningful if supply is secured at that price across the full SNIS network, and if mutual insurers have the administrative infrastructure to manage the new coverage lines without disruption to existing benefit management. The announcement does not address supply security, contract duration, or the consequences of non-compliance by any party. No analyst estimate of the aggregate fiscal impact has been published in the available record.

Uruguay’s parallel positioning as a regional pharmaceutical supply hub adds a layer of context. In September 2026, Minister Lustemberg described Uruguay as ‘a meeting point’ for pharmaceutical knowledge and innovation at the seventh annual ‘Uruguay Best Practices in Pharma Supply Chain’ event, according to reporting by Infobae citing EFE. Pharmaceutical, veterinary, and medical device exports reached USD 406 million in 2025, with pharmaceutical transit volumes at USD 969 million, per the same report. The domestic formulary expansion and the export-platform ambition are not inherently in tension, but they do place the MSP in the position of simultaneously pressing for lower acquisition prices and cultivating the industry relationships on which supply security depends.

The deeper signal is that Uruguay is testing whether collective negotiation at the SNIS level can substitute for the judicial channel as the primary mechanism for expanding access to high-cost medicines. If the 12-medicine agreement holds at the reported price without supply disruption or provider financial stress, it establishes a template. If it does not, the pressure will return to the courts — and the FNR’s USD 460 million envelope will face the same structural question it has faced for a decade.